NervGen Pharma (TSE:NGEN) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
NervGen Pharma Corp. successfully conducted its Annual General Meeting, with shareholders approving all proposed resolutions, re-electing the existing board, and appointing Glenn Ives and John Ruffolo as Chairs of the Board and Audit Committee, respectively. The company, which focuses on developing treatments for nervous system repair, also received shareholder support for amendments to its stock option plan, including an increase in shares reserved for issuance.
For further insights into TSE:NGEN stock, check out TipRanks’ Stock Analysis page.
